RxDoctor Payments Data

Amit Arora, MD

Neurology · Huntsville, ALNPI 1750598660

Payments from drug & device makers

$22,166in general payments, 2019–2025

Across 1,397 payments — averaging $15.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$3K
  • AbbVie$2K
  • Pfizer$2K
  • Novartis$1K
  • Amgen$935
  • Genentech USA, Inc.$737
  • plus $12K from 54 others

What the payments were for

  • Speaking & faculty fees$2861%
  • Food & beverage$21,65898%
  • Education$2211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.251$3,120
AbbVie(2 entities)196$2,342
Pfizer127$1,546
Novartis86$1,319
Amgen(2 entities)52$935
Genentech USA, Inc.42$737
Argenx US, Inc.28$728
MDD US Operations, LLC19$695
Acadia Pharmaceuticals Inc41$683
Neurocrine Biosciences, Inc.27$593
AstraZeneca(2 entities)26$559
Acorda Therapeutics, Inc30$547
Teva Pharmaceuticals USA, Inc.28$547
Lundbeck LLC31$523
SK Life Science, Inc.33$494
CSL Behring14$404
Sunovion Pharmaceuticals Inc.25$403
Adamas Pharmaceuticals, Inc.23$373
Lilly USA, LLC24$357
Biogen24$353
Otsuka America Pharmaceutical, Inc.18$353
Catalyst Pharmaceuticals, Inc.18$310
Neurelis, Inc.19$300
Eisai Inc.18$274
Upsher-smith Laboratories LLC15$271
TG Therapeutics, Inc.13$249
Merz Pharmaceuticals, LLC11$241
Grifols USA, LLC10$208
Supernus Pharmaceuticals, Inc.11$191
Biohaven Pharmaceuticals, Inc.9$191
Avanir Pharmaceuticals, Inc.11$189
Biohaven Pharmaceutical Holding Company Ltd.12$183
Greenwich Biosciences, Inc.6$182
EMD Serono, Inc.9$172
Johnson & Johnson(2 entities)6$130
Portola Pharmaceuticals, LLC7$126
Jazz Pharmaceuticals Inc.7$121
Takeda Pharmaceuticals U.S.A., Inc.6$113
Bristol Myers Squibb6$109
Octapharma USA, Inc.5$103
Kyowa Kirin, Inc.6$102
Aquestive Therapeutics, Inc.5$90
Axsome Therapeutics, Inc.3$60
Assertio Therapeutics, Inc.4$58
Sumitomo Pharma America, Inc.3$52
Xeris Pharmaceuticals, Inc.3$45
Ipsen Biopharmaceuticals, Inc2$43
Impel Pharmaceuticals Inc.3$43
Amneal Pharmaceuticals LLC3$40
Zyla Life Sciences, Inc.2$31
Boston Scientific1$31
Alnylam Pharmaceuticals Inc.1$29
Averitas Pharma Inc.1$24
Arbor Pharmaceuticals, Inc.2$23
Sanofi1$23
Akcea Therapeutics, Inc.1$23
ITF Therapeutics LLC1$22
Livanova USA, Inc.1$19
Zogenix Inc.1$17
Impel Pharmaceuticals LLC1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,166 in reported general payments places this provider in the 70th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama

Medicare billing

Part B allowed, 2024
$633,045
Medicare patients
1,196
Services billed
4,156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lacosamide422$78,483
Lamictal XrLamotrigine12$62,585
FycompaPerampanel22$58,426
NeuproRotigotine30$38,041
Memantine Hcl1,053$37,615
Levetiracetam512$20,029
Carbidopa-LevodopaCarbidopa/Levodopa488$20,009
Rivastigmine55$17,322
LamictalLamotrigine22$16,366
Donepezil Hcl1,096$12,631
DilantinPhenytoin Sodium Extended31$8,203
Pyridostigmine Bromide89$6,719
Memantine Hcl ErMemantine Hcl28$5,231
Primidone171$5,144
Divalproex Sodium218$4,444

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Eisai Inc.Fycompa$274$58,42622 claims
UCB, Inc.Neupro$3,120$38,04130 claims
PfizerDilantin$1,546$8,20331 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$40$6,71989 claims
Upsher-smith Laboratories LLCTopiramate$271$1,891158 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 255 neurology providers in Alabama.

Other neurology in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →